G

GH Research PLC
NASDAQ:GHRS

Watchlist Manager
GH Research PLC
NASDAQ:GHRS
Watchlist
Price: 9.24 USD 0.98% Market Closed
Market Cap: 480.8m USD
Have any thoughts about
GH Research PLC?
Write Note

Profitability Summary

GH Research PLC's profitability score is 32/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

32/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

32/100
Profitability
Score
32/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
GH Research PLC

Revenue
0 USD
Operating Expenses
-34.1m USD
Operating Income
-34.1m USD
Other Expenses
6.8m USD
Net Income
-27.3m USD

Margins Comparison
GH Research PLC Competitors

Country Company Market Cap Operating
Margin
Net
Margin
IE
GH Research PLC
NASDAQ:GHRS
480.7m USD N/A N/A
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
771.1B USD
35%
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
44%
35%
US
Johnson & Johnson
NYSE:JNJ
368.9B USD
28%
17%
US
Merck & Co Inc
NYSE:MRK
249.4B USD
34%
19%
CH
Roche Holding AG
SIX:ROG
209.8B CHF
32%
20%
CH
Novartis AG
SIX:NOVN
179.9B CHF
29%
33%
UK
AstraZeneca PLC
LSE:AZN
157.3B GBP
21%
13%
IE
Endo International PLC
LSE:0Y5F
155B USD
11%
-126%
Country IE
Market Cap 480.7m USD
Operating Margin N/A
Net Margin N/A
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 771.1B USD
Operating Margin
35%
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Operating Margin
44%
Net Margin
35%
Country US
Market Cap 368.9B USD
Operating Margin
28%
Net Margin
17%
Country US
Market Cap 249.4B USD
Operating Margin
34%
Net Margin
19%
Country CH
Market Cap 209.8B CHF
Operating Margin
32%
Net Margin
20%
Country CH
Market Cap 179.9B CHF
Operating Margin
29%
Net Margin
33%
Country UK
Market Cap 157.3B GBP
Operating Margin
21%
Net Margin
13%
Country IE
Market Cap 155B USD
Operating Margin
11%
Net Margin
-126%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
GH Research PLC Competitors

Country Company Market Cap ROE ROA ROCE ROIC
IE
GH Research PLC
NASDAQ:GHRS
480.7m USD
-13%
-12%
-16%
-38%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
771.1B USD
66%
13%
33%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
89%
27%
75%
35%
US
Johnson & Johnson
NYSE:JNJ
368.9B USD
20%
8%
18%
13%
US
Merck & Co Inc
NYSE:MRK
249.4B USD
28%
11%
25%
20%
CH
Roche Holding AG
SIX:ROG
209.8B CHF
40%
13%
29%
22%
CH
Novartis AG
SIX:NOVN
179.9B CHF
35%
16%
20%
15%
UK
AstraZeneca PLC
LSE:AZN
157.3B GBP
17%
6%
14%
12%
IE
Endo International PLC
LSE:0Y5F
155B USD
70%
-51%
5%
6%
Country IE
Market Cap 480.7m USD
ROE
-13%
ROA
-12%
ROCE
-16%
ROIC
-38%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 771.1B USD
ROE
66%
ROA
13%
ROCE
33%
ROIC
19%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country DK
Market Cap 3.3T DKK
ROE
89%
ROA
27%
ROCE
75%
ROIC
35%
Country US
Market Cap 368.9B USD
ROE
20%
ROA
8%
ROCE
18%
ROIC
13%
Country US
Market Cap 249.4B USD
ROE
28%
ROA
11%
ROCE
25%
ROIC
20%
Country CH
Market Cap 209.8B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country CH
Market Cap 179.9B CHF
ROE
35%
ROA
16%
ROCE
20%
ROIC
15%
Country UK
Market Cap 157.3B GBP
ROE
17%
ROA
6%
ROCE
14%
ROIC
12%
Country IE
Market Cap 155B USD
ROE
70%
ROA
-51%
ROCE
5%
ROIC
6%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top